CA
MRVI icon

CoreCap Advisors’s Maravai LifeSciences MRVI Stock Holding History

CoreCap Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-322
Closed -$712 – 3060
2025
Q1 		$712 Buy
+322
New +$1.27K ﹤0.01% 2600
2022
Q1 		– Sell
-48
Closed -$2K – 1476
2021
Q4 		$2K Buy
+48
New +$1.94K ﹤0.01% 1971

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CoreCap Advisors's MRVI Position: Q2 2025 in Review

CoreCap Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 322 shares — an estimated $712 sold.

CoreCap Advisors first reported a position in MRVI in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • CoreCap Advisors reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 322 Maravai LifeSciences shares in Q2 2025, an estimated $712.
  • CoreCap Advisors first reported a position in Maravai LifeSciences in Q4 2021 and held it in 2 quarters.
  • CoreCap Advisors's Maravai LifeSciences position peaked at $2K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.